Clinical Trial Update: Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a sequential regimen of bendamustine followed by GA101 and ibrutinib in patients with chronic lymphocytic leukemia (CLL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• GA101 (obinutuzumab)
• Ibrutinib (ibrutinib)

Snippet

Sponsor: German CLL Study Group | Conditions: Chronic Lymphocytic Leucemia | Phase 2 | Status: COMPLETED